Back to Search
Start Over
LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program
- Source :
- The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver, The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver, Apr 2015, Vienne, Austria. 62, Supplement 2, pp.S265--S266, 2015, ⟨10.1016/S0168-8278(15)30159-8⟩
- Publication Year :
- 2015
- Publisher :
- HAL CCSD, 2015.
-
Abstract
- International audience; no abstract
- Subjects :
- medicine.medical_specialty
Daclatasvir
Hepatology
Sofosbuvir
business.industry
Ribavirin
[SDV]Life Sciences [q-bio]
Compassionate Use
Interim analysis
Virology
3. Good health
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
chemistry
030220 oncology & carcinogenesis
Internal medicine
Genotype
Medicine
030211 gastroenterology & hepatology
In patient
business
ComputingMilieux_MISCELLANEOUS
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver, The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver, Apr 2015, Vienne, Austria. 62, Supplement 2, pp.S265--S266, 2015, ⟨10.1016/S0168-8278(15)30159-8⟩
- Accession number :
- edsair.doi.dedup.....15922c4439b10fc1be2148d901ea64f1
- Full Text :
- https://doi.org/10.1016/S0168-8278(15)30159-8⟩